Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal ...

Despite the regulatory setback, BioArctic's partner Eisai has stated that the safety profile of lecanemab reported in clinical practice in the United States, Japan, and other countries is consistent ...

AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...

The European Commission has published on the 29th January the “Competitiveness Compass for the EU”, setting out ambitious initiatives aimed ...

The European Commission (EC) has presented data regarding several criminal proceedings linked to the enforcement of EU law, with Bulgaria involved in seven of these cases. In the realm of crime ...

Unife has warned that EU member states are at risk of losing funding for vital rail schemes promised in the EU's Recovery and ...

The European Commission said on Friday that it has launched infringement procedures against Bulgaria for failing to fully ...

Merck (MRK) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, recommended ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Projects will contribute to the European Union’s 2030 target of 50 million tpa of CO2 injection capacity as bloc pushes to ...

Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ...